A股異動丨AI醫療概念股活躍,華大基因漲超13%創2023年4月以來新高
A股市場AI醫療概念股活躍,其中,華大基因漲超13%創2023年4月以來新高,科美診斷漲超12%,國際醫學、金域醫學、貝瑞基因10CM漲停,祥生醫療漲超9%,安必平、迪安診斷、辰光醫療漲超8%,超研股份、樂心醫療、達安基因漲超5%,偉思醫療、仁度生物、九強生物漲超4%。近期,多家醫療企業密集宣佈,公司已接入DeepSeek。互聯網醫療企業稱,DeepSeek可用於AI輔助診療、智能醫療服務等場景;醫療體檢企業認爲,DeepSeek可用於疾病監測、慢病管理等場景;中醫相關企業更是表示,DeepSeek可融入個性化中醫智能產品的設計。(格隆匯)

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.